Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                MCM Regulatory Science

MCM Regulatory Science

                        Animal Rule Information
          Extramural Research
          Intramural Research
          MCMi Regulatory Science Presentations
          Regulatory Science Research Tools Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          MCM Regulatory Science
          A new approach for understanding Ebola virus pathogenesisMCM Regulatory Science A new approach for understanding Ebola virus pathogenesis
  
  					Study expanded to gather important information about COVID-19 infection
	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Researchers in the Sabeti Lab prepare a genomics experiment. (Credit: Oliver Douliery, Broad Institute)

This project has been completed, and this page is no longer being updated. For new project updates, visit MCM Regulatory Science.


Overview | Project description | Project tasks | COVID-19 Update| Publications| Additional reading | Related links

*Image: Researchers in the Sabeti Lab prepare a genomics experiment. (Credit: Oliver Douliery, via Flickr)*

**Performer:**Broad Institute of MIT and Harvard**Project leader:** Professor Pardis C. Sabeti, M.D., D. Phil.**Initial contract value:**$942,075**Contract modification 1 value:** $555,760 (June 2020)**Contract modification 2 value:**$814,803 (March 2021)**Total contract value:** $2,312,638**Project dates:**November 2018 to September 2021

Overview

Infection with Ebola virus results in a series of complex events within the body that lead to disease—including immune suppression and organ-specific damage. In addition, how the Ebola virus evolves within the body is suspected to play a key role in Ebola virus disease progression.

The interaction among these factors and how they contribute to the overall effect the Ebola virus has on the body and the outcomes of infection remains poorly understood. This is in part because the Ebola virus spreads rapidly throughout the body, simultaneously affecting multiple organs, resulting in many changes in the body’s gene expression. These changes, as well as the Ebola virus evolution during infection and its effects on disease progression, are difficult to track and analyze.

Acquiring a deeper understanding of the biological mechanisms that contribute to Ebola virus disease is critical to developing medical countermeasures (MCMs) to prevent and treat Ebola virus disease.

Project description

In September 2018, FDA awarded a two-year contract to the Broad Institute to conduct the largest Ebola virus and host gene expression (i.e., transcriptomics) study to date. Researchers at the Broad Institute will use the latest sequencing technologies, including single-cell sequencing methods, to assess how Ebola virus evolves and spreads within the body. They also aim to identify mechanisms and biological pathways that are altered in immune cells and tissues throughout the body during infection. This work will inform the natural history of Ebola virus disease in humans and help characterize nonclinical models necessary for testing Ebola MCMs.

The contract also includes two option periods for potential Lassa virus research in future fiscal years.

This project builds on previous and ongoing research conducted by the National Institutes of Health (NIH) Integrated Research Facility(IRF) leveraging samples and knowledge developed from over more than a decade of collaborative Ebola and Lassa virus research between Broad Institute researchers, the NIH IRF, and the Department of Defense.

Project tasks

Using samples from previous NIH IRF research, the Broad Institute will:

**Study Ebola variation, evolution, host response, and circulation between tissues**by extracting RNA from a total of 20 sample types; measuring by spectrophotometry; performing PCR to extract sequencing-quality RNA; quantifying viral load; preparing 4 RNA-sequence libraries of 150 samples each; and sequencing each batch, generating a minimum of 5 million reads/pairs. They will then study and compare the sequences using various techniques.
	Use novel, portable, and low-cost Seq-Well technology to **quantify single-cell gene expression changes**between infected and non-infected peripheral blood mononuclear cells (PBMCs), to determine which cells are responsible for which changes in gene expression and identify shifts in immune cell populations over time.
	**Perform total RNA sequencing on a wide variety of tissue samples** collected at all stages of Ebola virus disease, to better understand how different tissues respond to Ebola infection and survey changes in host gene expression.
	**Optimize single-cell sequencing for Lassa virus and other viral hemorrhagic fevers**, to enable future studies needed for MCM development for these pathogens.This work will help fill significant gaps in the scientific community’s understanding of how Ebola virus disease progresses at the molecular level, which will help identify biological pathways and mechanisms that could be useful biomarkers to assess the efficacy of MCMs, or advance development of potential therapeutics. In addition, the models and methods established will enable future research important to MCM development for viral hemorrhagic fevers, including evaluation of investigational MCMs such as vaccines and therapeutics.

Update – March 2021 (COVID-19)

In March 2021, FDA modified this contract with the Broad Institute to apply the same technology (including single-cell RNA sequencing) used for the Ebola project to better understand viral infection, pathogenesis, and immune responses to SARS-CoV-2 in in vitro, nonclinical, and clinical studies. Ultimately, this study may help support development and inform FDA evaluation of medical countermeasures for COVID-19, including rapid diagnostics, therapeutics, and vaccines.

*This project was funded through the MCMi Regulatory Science Extramural Research program*

Publications

Santus, L., Sopena-Rios, M., García-Pérez, R., et al. (2023). Single-cell profiling of lncRNA expression during Ebola virus infection in rhesus macaques. In Nature Communications (Vol. 14, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41467-023-39627-7
	Delorey, T., Ziegler, C., Heimberg, G. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature [Accelerated Article Preview]; 2021 April 29. DOI: https://doi.org/10.1038/s41586-021-03570-8 - full text
	Kotliar, D., Lin, A., Logue, J. et al. Single-cell profiling of Ebola Virus Disease *I*n*Vivo* Reveals Viral and Host Dynamics. Cell; 2020 Nov 6. DOI: https://doi.org/10.1016/j.cell.2020.10.002
	Lemieux, J., Siddle, K., Shaw, B. et al.. Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events. Science 2021 Feb 5. DOI: https://doi.org/10.1126/science.abe3261
	Bartsch, Y., Fischinger, S., Siddiqui, S et al.  Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Comms 2021 Feb 15;12(1):1018. DOI: https://doi.org/10.1038/s41467-021-21336-8

Additional reading

Gire, Stephen K., Augustine Goba, Kristian G. Andersen, Rachel S. G. Sealfon, Daniel J. Park, Lansana Kanneh, Simbirie Jalloh, et al. 2014. “Genomic Surveillance Elucidates Ebola Virus Origin and Transmission during the 2014 Outbreak.” Science 345 (6202): 1369–72. doi: 10.1126/science.1259657

Gierahn, Todd M., Wadsworth II, Marc H., Hughes, Travis K., Bryson, Bryan D., Butler, Andrew., Satija, Rahul., Fortune, Sarah., et al. 2017. “Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput.” Nature Methods 14, 395-398 doi: 10.1038/nmeth.4179

Caballero, Ignacio S., Anna N. Honko, Stephen K. Gire, Sarah M. Winnicki, Marta Melé, Chiara Gerhardinger, Aaron E. Lin, et al. 2016. “In Vivo Ebola Virus Infection Leads to a Strong Innate Response in Circulating Immune Cells.” BMC Genomics 17 (September): 707. doi: 10.1186/s12864-016-3060-0

Park, Daniel J., Gytis Dudas, Shirlee Wohl, Augustine Goba, Shannon L. M. Whitmer, Kristian G. Andersen, Rachel S. Sealfon, et al. 2015. “Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone.” Cell 161 (7): 1516–26. doi: 10.1016/j.cell.2015.06.007

Rubins, Kathleen H., Lisa E. Hensley, Victoria Wahl-Jensen, Kathleen M. Daddario DiCaprio, Howard A. Young, Douglas S. Reed, Peter B. Jahrling, Patrick O. Brown, David A. Relman, and Thomas W. Geisbert. 2007. “The Temporal Program of Peripheral Blood Gene Expression in the Response of Nonhuman Primates to Ebola Hemorrhagic Fever.” Genome Biology 8 (8): R174. doi:  10.1186/gb-2007-8-8-r174

Related links

Single-cell study of Ebola highlights virus's lethal maneuvers
	Sabeti Lab
	Shalek Lab
	NIH Integrated Research Facility
	Research Highlights: Ebola (from the Broad Institute)
	Working with Ebola – Biosafety (from the Broad Institute)
	Ebola Preparedness and Response Updates from FDA

                                                                                  Content current as of:
      07/06/2023
              
              
Topic(s)
			  Research
				    				       				    				       BiologicalHealth Topic(s)
			  Coronavirus
			    			       			    			       EbolaMCM Regulatory Science

          
                        Animal Rule Information
          Extramural Research
          Intramural Research
          MCMi Regulatory Science Presentations
          Regulatory Science Research Tools
 Subscribe
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including regulatory science related to medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop